3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
19
Other
1
Head & Neck
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Paclitaxel
35
Bevacizumab
31
Carboplatin
29
pembrolizumab
25
Specimen Handling
20
Magnetic Resonance Spectroscopy
18
olaparib
16
Cisplatin
15
liposomal doxorubicin
13
Taxes
12
Immunoglobulin G
11
Gemcitabine
11
Disulfides
11
Topotecan
9
Nivolumab
9
Cyclophosphamide
9
Biopsy
8
fludarabine
7
Doxorubicin
7
mirvetuximab soravtansine
6
niraparib
5
Radiation
5
Oxaliplatin
5
Fulvestrant
5
Fluorouracil
5
trastuzumab deruxtecan
4
durvalumab
4
cediranib
4
Platinum
4
Megestrol Acetate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anastrozole
×
Gynecologic
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled